Reversal of P-glycoprotein related resistance by idarubicin

V. Nuessler, F. Gieseler, R. Pelka-Fleischer, E. Gullis, W. Abendhardt, P. Langenmayer, V. Heinemann, H. J. Kolb, W. Wilmanns

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Multidrug resistance is one type of chemotherapy resistance and related to two main mechanisms - the P-glycoprotein (P-gp) and DNA-Topoisomerases-related resistance. The following examination was used to test Idarubicin (IDR) efficacy in relation to P-glycoprotein expression and in its fractionated application form to also examine the quality of life in multiple pretreated leukemia patients. Idarubicin was given to 12 acute myelogenous leukemia (AML patients, 5 acute lymphoblastic leukemia (ALL patients and 5 chronic myelogenous leukemia (CML) patients in blast crisis (BC). Remission was achieved in 5/12 AML patients (5 partial remission) and in 3/5 ALL patients (3 partial remission) and in 2/5 CML in BC a minor response. After IDR treatment all patients with P-gp overexpression (≥ 15% positive cells in the bone marrow) showed a reduction of the P-gp positive cells. As a result of this, a partial remission (PR), minor response (MR) or stable disease (NC) was reached by the most patients for at least 2 months. The toxicity of this application form was tolerable. This study shows for the first time that P-glycoprotein related resistance can be reversed by IDR in multiple pretreated patients.

Original languageEnglish
Pages (from-to)S162-S163
JournalBone Marrow Transplantation
Issue numberSUPPL. 4
StatePublished - 1993
Externally publishedYes


Dive into the research topics of 'Reversal of P-glycoprotein related resistance by idarubicin'. Together they form a unique fingerprint.

Cite this